About the book
The book will be a recent update on multiple myeloma. It will aim to include several chapters covering various aspects of multiple myeloma including:
Diagnosis (clinical, radiological, cytogenetic, and molecular criteria), pathogenesis (risk factors, pre-myeloma conditions, and bone marrow microenvironment), cytogenetic abnormalities and molecular profiles disease staging and risk stratification, novel therapies such as proteasome inhibitors, immunomodulatory agents as well as monoclonal antibodies, drug resistance (primary and secondary resistance as well as evolution of new genetic mutations that may be disease or therapy-related), hematopoietic stem cell transplantation (HSCT) (autologous HSCT, allogeneic HSCT, and tandem transplantation), relapsed and refractory multiple myeloma, minimal residual disease (evaluation by flow cytometry or various sequencing techniques, importance of MRD in prognosis and prediction of disease relapse), chimeric antigen receptor (CAR) T-cell therapy, infectious complications in multiple myeloma (viral infections, bacterial infections, fungal infections, disease-related infections and therapy-related infections).
The book chapters will intend to be written by scientists and experts in the field from various institutions around the world.
